Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Pfizer Inc. PFE

Healthcare  —  Drug Manufacturers General
28.67 0.26 0.92% as of 25 Sep
Market cap
$161.7B
P/E
37.7×
S&P 500 Member Dividend Champion (10y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Pfizer Inc. (PFE) Business Profile

Updated before January 2025

Company Overview

Pfizer Inc. (PFE) is one of the world’s leading biopharmaceutical companies, headquartered in New York City, United States. The company was founded in 1849 by Charles Pfizer and Charles Erhart, two German-American cousins, in Brooklyn, New York. Initially, Pfizer focused on producing fine chemicals, but it later expanded into pharmaceuticals, becoming a global leader in the industry. Over the years, Pfizer has been at the forefront of medical innovation, contributing significantly to the development of vaccines, treatments, and therapies for various diseases.

Pfizer’s leadership team is spearheaded by Albert Bourla, who serves as the Chairman and Chief Executive Officer (CEO). Under his leadership, the company has focused on innovation, sustainability, and global health equity. Other key executives include Angela Hwang, Group President of Pfizer Biopharmaceuticals Group, and Mikael Dolsten, Chief Scientific Officer and President of Worldwide Research, Development, and Medical.

Core Business Segments

Pfizer operates through several core business segments, each focusing on specific therapeutic areas and product categories. These include:

1. Vaccines

Pfizer is renowned for its vaccine portfolio, which includes:

  • Comirnaty (COVID-19 Vaccine): Developed in partnership with BioNTech, this mRNA-based vaccine played a pivotal role in combating the COVID-19 pandemic.
  • Prevnar Family: A series of pneumococcal vaccines aimed at preventing infections caused by Streptococcus pneumoniae.
  • Trumenba: A vaccine for meningococcal group B disease.

2. Oncology

Pfizer has a robust oncology portfolio, offering treatments for various types of cancer, including:

  • Ibrance: A leading therapy for metastatic breast cancer.
  • Xtandi: Used for prostate cancer treatment.
  • Inlyta: A therapy for advanced renal cell carcinoma.

3. Rare Diseases

Pfizer addresses rare diseases with specialized treatments, such as:

  • Vyndaqel/Vyndamax: For transthyretin amyloid cardiomyopathy (ATTR-CM).
  • Hemophilia Treatments: Including gene therapies under development.

4. Inflammation and Immunology

This segment focuses on autoimmune and inflammatory diseases, with products like:

  • Xeljanz: A treatment for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
  • Cibinqo: For atopic dermatitis.

5. Internal Medicine

Pfizer offers therapies for cardiovascular and metabolic diseases, including:

  • Eliquis: A widely used anticoagulant.
  • Lipitor: A cholesterol-lowering medication.

6. Anti-Infectives

Pfizer provides antibiotics and antifungal medications, such as:

  • Zyvox: For bacterial infections.
  • Sulfatrim: For urinary tract infections and other bacterial conditions.

7. Consumer Healthcare (Legacy Segment)

Although Pfizer divested its consumer healthcare business in a joint venture with GSK, it previously offered over-the-counter products like Advil and Centrum.

Business Model

Pfizer’s business model revolves around research, development, manufacturing, and commercialization of innovative medicines and vaccines. The company invests heavily in R&D to discover and develop new therapies, often collaborating with academic institutions, biotech firms, and other pharmaceutical companies. Revenue is primarily generated through the sale of prescription medicines, vaccines, and therapies.

Pfizer also adopts a patient-centric approach, ensuring accessibility and affordability of its products globally. The company leverages advanced technologies, such as mRNA platforms, to accelerate drug development and improve efficacy. Additionally, Pfizer’s global supply chain and manufacturing capabilities enable it to meet the demands of diverse markets efficiently.

Strategic Direction

Pfizer’s strategic direction focuses on innovation, sustainability, and global health equity. Key initiatives include:

  • Pipeline Expansion: Pfizer is actively developing new therapies in oncology, rare diseases, and gene therapy. The company has over 90 projects in various stages of clinical development.
  • Sustainability Goals: Pfizer aims to achieve carbon neutrality by 2030 and reduce its environmental footprint through sustainable manufacturing practices.
  • Digital Transformation: The company is leveraging digital technologies and data analytics to enhance R&D efficiency and improve patient outcomes.
  • Global Health Equity: Pfizer is committed to improving access to medicines and vaccines in low- and middle-income countries through initiatives like the “An Accord for a Healthier World.”

Competitive Landscape

Pfizer operates in a highly competitive pharmaceutical industry, facing competition from both large multinational corporations and smaller biotech firms. Key competitors include:

  • Johnson & Johnson: Competes in vaccines, oncology, and immunology.
  • Merck & Co.: Known for its oncology and vaccine portfolio, including Keytruda and Gardasil.
  • Moderna: A major competitor in the mRNA vaccine space.
  • Roche: Focuses on oncology and diagnostics.
  • Novartis: Competes in oncology, cardiology, and gene therapy.

Risk Factors

Pfizer faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: Reliance on key products like Comirnaty and Eliquis for a significant portion of revenue.
  • Regulatory Challenges: Stringent regulatory requirements and potential delays in drug approvals.
  • Supply Chain Disruptions: Vulnerability to raw material shortages and manufacturing issues.
  • Patent Expirations: Loss of exclusivity for major products, leading to generic competition.
  • Litigation Risks: Exposure to lawsuits related to product safety and intellectual property.

Recent Developments

  • COVID-19 Vaccine Updates: Pfizer continues to update its Comirnaty vaccine to address emerging variants and expand its use in pediatric populations.
  • Acquisitions: In 2023, Pfizer acquired Seagen, a leader in antibody-drug conjugates, to strengthen its oncology portfolio.
  • New Approvals: Recent FDA approvals include Cibinqo for atopic dermatitis and Prevnar 20 for pneumococcal disease prevention.
  • Global Expansion: Pfizer has expanded its manufacturing capabilities in emerging markets to improve global access to medicines.

Investment Considerations

Strengths:

  • Strong R&D pipeline with innovative therapies.
  • Leadership in vaccines and oncology.
  • Robust financial performance and dividend payouts.
  • Global presence and manufacturing capabilities.

Risks:

  • Dependence on a few key products for revenue.
  • Exposure to regulatory and litigation risks.
  • Competition from generics and biosimilars.

Conclusion

Pfizer Inc. is a global leader in the pharmaceutical industry, known for its innovative medicines and vaccines. With a strong R&D pipeline, strategic acquisitions, and a commitment to sustainability, Pfizer is well-positioned for future growth. However, investors should consider the risks associated with market dependence and regulatory challenges. Overall, Pfizer remains a key player in advancing global health and addressing unmet medical needs.